Problem

Insurf addresses the administrative and financial burden of prior authorizations and denied healthcare claims. Providers must assemble clinical evidence, satisfy payer-specific requirements, obtain physician review, submit appeals, and chase decisions—work that is repetitive, deadline-sensitive, and often left undone. The economics are material: one industry survey estimated that claim denials cost healthcare organizations $262 billion annually, while Insurf cites 2024 Medicare Advantage data showing that only 11.5% of denied prior-authorization requests were appealed, even though 80.7% of appealed denials were partially or fully overturned.

The clearest use case is helping hospitals and specialty practices recover high-value revenue from clinical denials before those claims age into write-offs. Insurf also targets prior-authorizations, where completing the administrative workflow can accelerate access to treatment while reducing the burden on nurses, medical assistants, and billing staff.

Product / Service

Insurf’s first product, Inveto, is an end-to-end workflow for prior authorizations and denial appeals. It accepts a prior-authorization request or denial appeal, creates a source-cited draft, coordinates physician review and attestation, leaves submission under the customer’s staff control, follows up with the payer, and reports the outcome. The six-step process covers intake, drafting and citation, physician review, staff-controlled submission, follow-up, and outcome reporting.

The delivery model is designed to fit existing provider systems and submission channels rather than require deep integration at the outset. Inveto tracks receipt, deadlines, payer decisions, and—when applicable—posted payment, while preserving clinical judgment with the physician and maintaining customer control over submission. Insurf presents the service as accountable workflow management, including a contractual fee credit when an in-scope deadline is missed, with the benefit of protecting earned revenue and giving provider teams time back.

Market

Insurf competes in health-insurance insurtech, with a more specific position at the intersection of AI-native decision infrastructure, healthcare revenue-cycle management, denial and appeal management, and prior-authorization automation. Its clearest adjacent competitors include Waystar, whose denial product uses generative AI to create appeal packages and payer-specific forms, and Tandem, which automates prior authorizations, appeal letters, and related medication-access work. Insurf differentiates its initial workflow through source-cited, physician-attested drafts, staff-controlled submission, and follow-through through the payer decision.

The company is very early: Y Combinator lists Insurf as an active Summer 2026 company founded in 2026 with a two-person team, while Dealroom records a $125,000 Y Combinator seed investment in June 2026. Its public terms refer to paid customer pilots, but the available public record does not disclose revenue or named customers, so it is best characterized as pilot-stage rather than a scaled commercial vendor. Longer term, Insurf says that resolved claims will build a proprietary coverage-decision graph for Surely, a planned product intended to help employers and brokers price the true cost of health plans.